Abstract
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. It represents the fifth most common cancer worldwide, and one whose incidence is on the rise. Liver cancer is the third most common cause of cancer mortality globally and thus a major health concern worldwide. Therapeutic options for this tumor include surgical resection, local ablative therapies, and systemic treatment. Liver transplantation has emerged as a highly effective treatment for patients with HCC, particularly in the setting of significant underlying liver disease. Current protocols in transplantation for this tumor utilize strict size criteria and staging (TNM classification) to select patients for this therapy. Selection criteria for liver transplantation for HCC that are accepted in the U.S. include: 1 tumor < 5cm, no greater than three tumor nodules, each less than 3cm in diameter 3) no macroscopic invasion of blood vessels or lymph nodes, and no extra-hepatic spread of tumor. Eligibility criteria and immunosuppression strategies are continuing to evolve in this field. Nonetheless, in appropriately selected patients, liver transplantation may provide a cure for HCC with survival rates equal to that of liver transplantation for end-stage liver disease (ESLD) from other causes. Liver transplantation has been established as one of the principal treatment modalities for this difficult disease.
Keywords: HCC, therapies, liver transplantation, liver surgery
Current Pharmaceutical Design
Title: Liver Transplantation for Hepatocellular Carcinoma: Current Role and Future Opportunities
Volume: 13 Issue: 32
Author(s): Felicitas L. Koller, Sunil K. Geevarghese and D. Lee Gorden
Affiliation:
Keywords: HCC, therapies, liver transplantation, liver surgery
Abstract: Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. It represents the fifth most common cancer worldwide, and one whose incidence is on the rise. Liver cancer is the third most common cause of cancer mortality globally and thus a major health concern worldwide. Therapeutic options for this tumor include surgical resection, local ablative therapies, and systemic treatment. Liver transplantation has emerged as a highly effective treatment for patients with HCC, particularly in the setting of significant underlying liver disease. Current protocols in transplantation for this tumor utilize strict size criteria and staging (TNM classification) to select patients for this therapy. Selection criteria for liver transplantation for HCC that are accepted in the U.S. include: 1 tumor < 5cm, no greater than three tumor nodules, each less than 3cm in diameter 3) no macroscopic invasion of blood vessels or lymph nodes, and no extra-hepatic spread of tumor. Eligibility criteria and immunosuppression strategies are continuing to evolve in this field. Nonetheless, in appropriately selected patients, liver transplantation may provide a cure for HCC with survival rates equal to that of liver transplantation for end-stage liver disease (ESLD) from other causes. Liver transplantation has been established as one of the principal treatment modalities for this difficult disease.
Export Options
About this article
Cite this article as:
Koller L. Felicitas, Geevarghese K. Sunil and Gorden Lee D., Liver Transplantation for Hepatocellular Carcinoma: Current Role and Future Opportunities, Current Pharmaceutical Design 2007; 13 (32) . https://dx.doi.org/10.2174/138161207782360591
DOI https://dx.doi.org/10.2174/138161207782360591 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on Metal Nanoparticles from Medicinal Plants: Synthesis, Characterization and Applications
Nanoscience & Nanotechnology-Asia Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Advances on Semisynthesis, Total Synthesis, and Structure-Activity Relationships of Honokiol and Magnolol Derivatives
Mini-Reviews in Medicinal Chemistry Patent Survey of Resveratrol, Taxol, Podophyllotoxin, Withanolides and Their Derivatives Used in Anticancer Therapy
Recent Patents on Biotechnology Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design Immunotherapy in Invasive Fungal Infection - Focus on Invasive Aspergillosis
Current Pharmaceutical Design The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer
Current Cancer Drug Targets 4-Hydroxynonenal in the Pathogenesis and Progression of Human Diseases
Current Medicinal Chemistry Analytical Methods for Metallothionein Detection
Current Analytical Chemistry Nanophytomedicine Based Novel Therapeutic Strategies in Liver Cancer
Current Topics in Medicinal Chemistry Advances in the Use of Multifunctional Mesoporous Silica Nanoparticles and Related Nanomaterials as Carriers for the Cancer Treatment
Current Drug Metabolism Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Current Chemical Biology CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets Angiogenesis and Hypoxia in Glioblastoma: A Focus on Cancer Stem Cells
CNS & Neurological Disorders - Drug Targets The 21st Century Form of Vitamin E - Tocotrienol
Current Pharmaceutical Design Applications of X-Ray Diffraction Imaging to Mammography
Recent Patents on Medical Imaging Styrene Maleic Acid Neocarzinostatin Treatment for Hepatocellular Carcinoma
Current Medicinal Chemistry - Anti-Cancer Agents Editorial [Hot Topic Lipohepatotoxicity and Nonalcoholic Steatohepatitis (NASH)-Like Metabolic Disorders (Guest Editor: Mustapha Cherkaoui-Malki)]
Current Drug Metabolism